版本:
中国

BRIEF-Halozyme provides update on SWOG Collaborative Group clinical study

March 30 Halozyme Therapeutics Inc:

* Halozyme provides update on swog collaborative group clinical study

* SWOG phase 1B/2 trial has been temporarily closed to enrollment

* Halozyme - Halozyme is working with SWOG to verify and analyze initial data set following completion of retrospective determination of tumor HA levels

* Halozyme-Addition of PEGPH20 given every two weeks unlikely to demonstrate statistically significant improvement in primary endpoint of overall survival Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐